Multimodality Therapy Improves Survival in Intramedullary Spinal Cord Metastasis of Lung Primary

Background: Most metastatic spinal cord lesions are located either in the intradural, extramedullary, or in the epidural compartments. Intramedullary spinal cord metastasis (ISCM) is a rare central nervous system spread of cancer. The aim of this report was to evaluate ISCM in the published literature. Methods: A literature review of PubMed from 1960 to 2016 was undertaken for the publications having demographic, clinical, histological, and outcome data. Results: A total of 59 relevant papers were identified, showing 128 cases of intramedullary metastasis from lung cancer. The incidence of lung cancer as the primary malignancy with intramedullary metastasis was 56%. The median time from diagnosis of primary to intramedullary metastasis was 6 months. Survival improved with multimodality therapy compared to monotherapy (4 months vs. 6.3 months) (hazard ratio = 0.501; 95% confidence interval, 0.293–0.857). Conclusion: Lung cancer is the predominant cause of intramedullary involvement of the spinal cord. Overall prognosis is poor, although a multimodality approach was associated with improved survival

Inguinal lymph node metastasis of colon cancer

We present a case of adenocarcinoma of colon with unusual metastasis to inguinal lymph nodes. Our patient is a young male with bilateral inguinal lymphadenopathy, bone pains, and jaundice who presented as carcinoma of unknown primary. He was diagnosed as widely metastatic adenocarcinoma of colon for which he received chemotherapy and has had a good response to the treatment

A Review of an Unfavorable Subset of Breast Cancer: Estrogen Receptor Positive Progesterone Receptor Negative

This review highlights the role of the progesterone receptor in breast cancer and discusses a significant subset of breast cancers that are estrogen receptor positive and progesterone receptor negative, and provides insight into the epidemiology, development, treatment concepts, prognosis, and resistance of these tumors to selective estrogen receptor modulators like tamoxifen